Five-year clinical outcomes following drug-eluting stent implantation in left main trifurcations

Robert J. Gil¹, Jacek Bil¹, Adam K. Kern², Luis A. Inigo Garcia³, Radoslaw Formuszewicz⁴, Slawomir Dobrzycki⁵

¹Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland
²Department of Cardiology and Cardiosurgery, University of Warmia and Mazury, Olsztyn Poland
³Department of Cardiology, Costa del Sol Hospital, Marbella, Spain
⁴Department of Cardiology, 10th Clinical Military Hospital, Bydgoszcz, Poland
⁵Department of Invasive Cardiology, Medical University in Bialystok, Bialystok, Poland

Introduction

Left main (LM) trifurcations are encountered in about 10–20% of LM cases and may require specific treatment strategies [1].

Aim

The aim of this retrospective analysis was to assess the effectiveness and safety of percutaneous coronary interventions with deployment of drug-eluting stents (DES) (both regular drug-eluting stents (rDES) and dedicated bifurcation BISS stents) in LM trifurcations in patients with stable coronary artery disease (CAD) and non-ST elevation acute coronary syndrome (NSTE-ACS).

Material and methods

Study population

We retrospectively analyzed data from the BISS Expert Registry, the international randomized clinical trial POLBOS I with BISS Expert, the BISS LIM Registry and the international randomized clinical trial POLBOS I with BISS LIM [2–6]. Patients with a final diagnosis of stable CAD or NSTE-ACS were enrolled between 2010 and 2013 in centers in Poland, Spain and Bulgaria. All patients signed the informed consent. Patients with STEMI or Medina type 001 bifurcation lesions were excluded from the registry. Provisional T-stenting (PTS) was the obligatory strategy.

The BISS is a coronary, dedicated balloon-expandable bifurcation stent. The platform is made of 316L stainless steel (strut thickness 120 μm) and the stent is coated with a biodegradable polymer that elutes paclitaxel (BISS Expert – paclitaxel concentration 1 μg/mm²) or sirolimus (BISS LIM – sirolimus concentration – 1.4 μg/mm²). The BISS stent consists of two parts, proximal and distal, joined with two connection struts at the middle zone [7]. In the rDES group, the use of any approved rDES available in participating catheterization laboratories was allowed. The POLBOS I trial started in 2010 when paclitaxel-eluting stents were routinely used. The following regular paclitaxel-eluting stents were used: Luc-Chopin2 (1 μg/mm², Balton), Coroflex Please (1 μg/mm², B. Braun), Taxcor (1 μg/mm², Eurocor) and Apollo (1 μg/mm², IK), whereas olimus-eluting stents were as follows: everolimus-eluting stents (Xience, Abbott Vasc; Promus, Boston Scientific), sirolimus-eluting stents (Cypher, Cordis; Prolim, Balton; Orsino, Biotronik; Cre8, CiD), biolimus-eluting stents (Biomime, Biomime; Biomatrix, Biosensors) and zotarolimus-eluting stents (Resolute Integrity, Medtronic).

Follow-up

Clinical follow-up was performed with office visits or by telephone at 12, 24, 36, 48 and 60 months after the intervention. Adverse events were monitored throughout the study period.

Endpoints

The primary endpoint was the cumulative rate of major adverse cardiovascular events (MACE) consisting of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR). Secondary endpoints included cardiac death, all-cause death, MI, TLR, target vessel revascularization (TVR), stent thrombosis (ST), and device success [8]. Cardiac death included death resulting from an acute MI, sudden cardiac death, death due...
to heart failure, and death due to cardiac procedures. All deaths were deemed cardiac unless proven otherwise. Myocardial infarction was defined according to the third universal definition [9].

**Statistical analysis**

Continuous variables were presented as mean ± SD. Categorical data were presented as numbers (%). Continuous variables were compared using an unpaired Student two-sided t test, and categorical data using the χ² test or Fisher’s exact test, as appropriate. If the distribution was not normal (verified with the Shapiro-Wilk test), the Wilcoxon signed-rank test and the Mann-Whitney U-test were used. The analysis of time to event was performed with the Kaplan-Meier estimator of survival curve. A log-rank test was used to compare survival distributions. P-values of < 0.05 were considered statistically significant. Statistical analyses were performed using R 3.0.2 for OS (R Foundation, Vienna, Austria).

**Results**

The analyzed population consisted of 245 patients, in whom 189 patients had a BioSS stent deployed in the distal LM and 56 patients rDES. In this population we identified 178 (72.7%) cases with distal LM bifurcation and 67 (27.3%) cases with distal LM trifurcation. Additionally, we differentiated three types among trifurcations: true trifurcations treated with only one stent (BioSS or rDES) (type I: n = 12, 17.9%), true trifurcations treated with 2- or 3-stent technique (type II: n = 36, 53.7%) and pseudo-trifurcations with high take-off of diagonal or marginal branches (type III: n = 19, 28.4%). The mean age of enrolled patients (82.1% males) was 66.8 ±9.77 years. All stents were implanted successfully (mean pressure 12 atm). In 45 (67.2%) cases the second stent was implanted within the side branch, mainly using T and protrusion (TAP) technique (including 9 cases from type III). In 64.2% of cases procedures were performed from radial access, and 20.9% using a 7 Fr guiding catheter. Detailed characteristics are presented in Table I.

In 14 (20.9%) cases peri-procedural MI was diagnosed. At 12 months there were no statistically significant differences between LM trifurcation types in MACE rates, 0, 11.1% (n = 4), 10.5% (n = 2), respectively. At 5-year follow-up the MACE rate for the whole study group was 19.4% (n = 13), whereas MACE rates for type 1, type 2 and
type 3 were 8.3%, 22.2% and 21.1%, respectively (Figure 1, Table II). No significant differences were observed between BIoSS and rDES subgroups (data not shown). Among 10 cases of TLR CABG was done in 2 cases, PCI with DES in 5, and PCI with drug-eluting balloon (DEB) in 3 cases.

Discussion
There are scarce data in the literature on the treatment of trifurcation left main disease. This is currently one of the largest reported cohorts of patients with unprotected LM stenosis treated with PCI and DES implantation with the longest follow-up [10]. Most studies have 3-year follow-up or assess bare metal stents; therefore it is difficult to compare MACE rates [10–12]. Nevertheless, our results of LM trifurcation stenting are in agreement with previous studies [13, 14]. The overall relatively high rate of adverse events was mostly driven by a high TLR rate. There was no significant difference compared to distal unprotected LM bifurcation treatment (Figure 1, Table II).

Limitations
The use of multiple stent types and drugs among rDES was a limitation, although this aspect of the design was intended to replicate real-world clinical practice. Also, the low number or rDES might influence the final outcome data compared with dedicated bifurcation stents.

Conclusions
Distal left main trifurcations are challenging lesions, but they can be successfully treated percutaneously with second generation drug-eluting stents, including dedicated bifurcation stents.

Conflict of interest
RJ. Gil is a Balton medical consultant. Other authors declare no conflict of interest.

References
1. Reig J, Petit M. Main trunk of the left coronary artery: anatomic study of the parameters of clinical interest. Clin Anat 2004; 17: 6-13.
2. Gil RJ, Bil J, Kern A, et al. Regular drug-eluting stents versus dedicated bifurcation drug-eluting BIoSS(R) stents for coronary bifurcation treatment: four-year results of randomized POLBOS I and POLBOS II clinical trials. EuroIntervention 2018; pii: EIJ-D-18-00172. doi: 10.4244/EIJ-D-18-00172.
3. Gil RJ, Bil J, Grundeken MJ, et al. Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting
Outcomes after DES implantation in left main trifurcations

BiOSS LIM(R) stent: the randomised, multicentre, open-label, controlled POLBOS II trial. EuroIntervention 2016; 12: e1404-12.

4. Gil RJ, Bil J, Grundeken MJ, et al. Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM(R) dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry. EuroIntervention 2016; 12: 1246-54.

5. Gil RJ, Bil J, Dzavik V, et al. Regular drug-eluting stent vs dedicated coronary bifurcation biox expert stent: multicenter open-label randomized controlled POLBOS I trial. Can J Cardiol 2015; 31: 671-8.

6. Bil J, Gil RJ, Vassilev D, et al. Dedicated bifurcation paclitaxel-eluting stent BiOSS Expert(R) in the treatment of distal left main stem stenosis. J Interv Cardiol 2014; 27: 242-51.

7. Gil RJ, Bil J, Vassilev D. The BiOSS stent. EuroIntervention 2015; 11 Suppl V: V153-4.

8. Bil J, Gil RJ, Kern A, et al. Novel sirolimus-eluting stent Prolim(R) with a biodegradable polymer in the all-comers population: one year clinical results with quantitative coronary angiography and optical coherence tomography analysis. BMC Cardiovasc Disord 2015; 15: 150.

9. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020-35.

10. Ielasi A, Takagi K, Latib A, et al. Long-term clinical outcomes following drug-eluting stent implantation for unprotected distal trifurcation left main disease: the Milan-New Tokyo (MITO) registry. Catheter Cardiovasc Interv 2014; 83: 530-8.

11. Sheiban I, Gerasimou A, Bollati M, et al. Early and long-term results of percutaneous coronary intervention for unprotected left main trifurcation disease. Catheter Cardiovasc Interv 2009; 73: 25-31.

12. Kubo S, Kadota K, Sabbah M, et al. Clinical and angiographic outcomes after drug-eluting stent implantation with triple-kissing-balloon technique for left main trifurcation lesion: comparison of single-stent and multi-stent procedures. J Invasive Cardiol 2014; 26: 571-8.

13. Shammas NW, Shammas GA, Jerin M, et al. Treatment of left main coronary trifurcation lesions with the paclitaxel drug-eluting stent: mid-term outcomes from a tertiary medical center. J Invasive Cardiol 2009; 21: 321-5.

14. Chen SL, Ye F, Zhang JJ, et al. Prediction of clinical outcomes in patients with unprotected left main trifurcation lesions treated by drug-eluting stents: importance of 2-stent technique and SYNTAX score. J Interv Cardiol 2010; 23: 352-7.